Robotic cataract laser maker Lensar's Q4 revenue falls on system sales decline

LENSAR

31/03/2026 11:13

Overview

U.S. robotic cataract laser maker's Q4 revenue fell 4% yr/yr, recurring revenue rose 17%

Net loss for Q4 narrowed sharply compared to prior year, driven by warrant liability changes

Company terminated Alcon merger, will retain $10 mln deposit as other income in Q1 2026

Outlook

Company did not provide specific guidance for the current qtr or full yr

Result Drivers

SYSTEM SALES DECLINE - Lower Q4 revenue was primarily driven by a $2.6 mln decrease in system revenue

PROCEDURE VOLUME GROWTH - Worldwide procedure volume increased about 20% in Q4, boosting recurring revenue

ALLY SYSTEM ADOPTION - ALLY installed base grew 48% over prior year, supporting higher utilization and recurring revenue

Company press release: ID:nGNX7rKFyy

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$1.5 mln
Q4 EBITDA
-$435,000


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for LENSAR Inc is $10.00, about 70.4% above its March 30 closing price of $5.87

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)